Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage
Status: Recruiting
Location: See location...
Intervention Type: Drug, Device
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
To provide a treatment of both actinic keratoses and photodamage within one treatment.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• Over 18yrs of age
• Willingness to participate in all required study activities and visits
• Willingness to sign the informed consent form
• Visible and palpable signs of diffuse actinic damage and actinic keratoses of mild to moderate severity located on the face
• Significant signs of photoaging, evaluated by investigator, that include any or all the following:
‣ Dyspigmentation
⁃ Solar lentigines
⁃ Telangiectasias
⁃ Diffuse erythema
⁃ Roughness and other textural changes
⁃ Fine lines
⁃ Wrinkles
⁃ Actinic bronzing
Locations
United States
New York
Rochester Dermatologic Surgery
RECRUITING
Victor
Contact Information
Primary
Catherine VanHooft, BA, CCRC
catherine@rochesterdermsurgery.com
585-222-1412
Time Frame
Start Date: 2025-06-27
Estimated Completion Date: 2026-02-01
Participants
Target number of participants: 10
Treatments
Experimental: Two PDT treatments
Each subject will receive 2 treatments of photodynamic therapy using Ameluz and HEROic BBL to treat facial AK and signs of photodamage.
Related Therapeutic Areas
Sponsors
Leads: Sherrif Ibrahim
Collaborators: Sciton, Biofrontera Bioscience GmbH